COREVALVE TRANSCATHETER AORTIC VALVE
Report
- Report Number
- 2025587-2017-02068
- Event Type
- Injury
- Date Received
- November 9, 2017
- Date of Event
- July 29, 2015
- Report Date
- November 9, 2017
- Manufacturer
- MEDTRONIC HEART VALVES DIVISION
- Product Code
- NPT
- PMA / PMN Number
- P130021
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- TU
- Reporter Occupation
- PHYSICIAN
Narratives
CITATION: ELVIN KESIMCI. IMPACT OF DIFFERENT ANESTHETIC MANAGEMENTS IN OUTCOMES OF TRANSCATHETER AORTIC VALVE IMPLANTATION: THE FIRST TURKISH EXPERIENCE. TURK J MED SCI. 2016; 46: 742-748. DOI: 10.3906/SAG-1503-74 EARLIEST DATE OF PUBLISH USED FOR EVENT DATE. NO UNIQUE DEVICE IDENTIFIER (SERIAL/LOT) NUMBERS WERE PROVIDED; WITHOUT THIS INFORMATION IT COULD NOT BE DETERMINED WHETHER THESE OBSERVATIONS HAVE BEEN PREVIOUSLY REPORTED. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.
MEDTRONIC RECEIVED INFORMATION VIA LITERATURE REGARDING THE IMPACT OF DIFFERENT ANESTHETIC MANAGEMENTS IN OUTCOMES OF TRANSCATHETER AORTIC VALVE IMPLANTATION. ALL DATA WERE COLLECTED FROM A SINGLE CENTER BETWEEN JULY 2011 AND JANUARY 2014. THE STUDY POPULATION INCLUDED 151 PATIENTS (PREDOMINANTLY FEMALE; MEAN AGE 76 YEARS), 54 OF WHICH WERE IMPLANTED WITH MEDTRONIC COREVALVE(R) REVALVING SYSTEM (CRS) (SERIAL NUMBERS NOT PROVIDED). AMONG ALL PATIENTS ADVERSE EVENTS INCLUDED: HEMODYNAMIC INSTABILITY, VASCULAR COMPLICATIONS, RHYTHM DISTURBANCES, AND PERMANENT PACEMAKER IMPLANTATION. MULTIPLE MANUFACTURERS WERE NOTED IN THE LITERATURE; BASED ON THE AVAILABLE INFORMATION A DIRECT CORRELATION COULD NOT BE MADE BETWEEN THE OBSERVED ADVERSE EVENTS AND MEDTRONIC PRODUCT. NO ADDITIONAL ADVERSE PATIENT EFFECTS WERE REPORTED.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 793639 | COREVALVE TRANSCATHETER AORTIC VALVE | AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIVERED | NPT | MEDTRONIC HEART VALVES DIVISION | CRS |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 76 YR | Required Intervention |